About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
A body of literature has demonstrated that inflammatory cytokines activate many of the molecular pathways involved in skeletal muscle wasting, leading to an imbalance between protein synthesis and degradation [4,5]
Think of collagen as a hard, fibrous protein which holds our bodies together and gives our skin a natural elasticity
Ethics statement Use of human erythrocytes was approved by the La Trobe University Research Ethics Committee (ethics number HEC17013) and an Australian Red Cross Blood Service Agreement (Deed 19-05VIC76 01)
2017;11:S42932